It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical Information Request
Medical Information Request


 

Our commitment to ongoing
communication on safety

A verified up-to-date source of safety information
from clinical trials and post-marketing experience with
ofatumumab for Healthcare Professionals

Website last update*: December 2021

As of September 25, 2021, a total of approximately 2,560 patients with relapsing multiple sclerosis (RMS) received ofatumumab in clinical trials including the ongoing open-label extension and  there was approximately 4,713 patient-years post marketing experience1

Home_Page
Home button

Report an adverse event

 
References
1. Data on file. Periodic Safety Update Report (Cut-off date: 25 September, 2021). Novartis Pharma AG.
*Last update included exposure, Ig levels, PML, fatalities, COVID-19, pregnancy, pivotal trial, references and FAQ sections